Latest papers

Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam.

An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.

Refractory Generalized Anxiety Disorder

Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Prodrugs of perzinfotel with improved oral bioavailability.

Zopiclone and sleepwalking.

A novel intramolecular Ugi reaction with 7-azabicyclo[2.2.1]heptane derivatives followed by post-condensation acylations: a new entry to azanorbornyl peptidomimetics.

In vivo saturation binding of GABA-A receptor ligands to estimate receptor occupancy using liquid chromatography/tandem mass spectrometry.

Viral genome cleavage with artificial ribonucleases: a new method to inactivate RNA-containing viruses.

Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Zopiclone-associated methemoglobinemia and renal impairment.

Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

A new hexaaza bicyclic cyclophane with dual binding sites.

Utility of flumazenil in zopiclone overdose.

3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators.

Total synthesis of (-)-aplaminal.

Pharmacological characterization of 3-azabicyclo[3,2,1] octane-1-yl-l-leucyl-d-tryptophanyl-d-4-Cl-phenylalanine: A novel ETA receptor-selective antagonist

Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. In regard to Anscher MS et al. (Int J Radiat Oncol Biol Phys 2008;71:1-9).

Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep?